Ascent Wealth Partners’s ImmunityBio IBRX Stock Holding History

Ascent Wealth Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,000	Closed	-$27.8K	–	166
2023 Q2	$27.8K	Buy	+10,000	New	+$28.3K	﹤0.01%	156

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Ascent Wealth Partners's IBRX Position: Q3 2023 in Review

Ascent Wealth Partners sold out of ImmunityBio (IBRX) in Q3 2023, closing a stake of 10,000 shares — an estimated $27.8K sold.

Ascent Wealth Partners first reported a position in IBRX in Q2 2023 and held it in 1 quarter. The position peaked at $27.8K in Q2 2023. 131 funds tracked by Wall St. Rank hold IBRX as of Q3 2023.

Ascent Wealth Partners reported no remaining ImmunityBio position as of Q3 2023 after selling out during the quarter.
Ascent Wealth Partners sold 10,000 ImmunityBio shares in Q3 2023, an estimated $27.8K.
Ascent Wealth Partners first reported a position in ImmunityBio in Q2 2023 and held it in 1 quarter.
Ascent Wealth Partners's ImmunityBio position peaked at $27.8K in Q2 2023.
131 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2023.

Based on Ascent Wealth Partners's 13F filing for Q3 2023, filed 20 Oct 2023.